Terms: = Pancreatic cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
25 results:
1. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
2. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract] [Full Text] [Related]
3. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based shp2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
4. shp2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
[TBL] [Abstract] [Full Text] [Related]
5. miR-6071 inhibits hepatocellular carcinoma progression via targeting ptpn11.
Chen M; Wang H; Shi S; Zhang H; Xu S; Jiang Y
Arch Biochem Biophys; 2022 Sep; 727():109345. PubMed ID: 35792156
[TBL] [Abstract] [Full Text] [Related]
6. Human Norovirus Triggers Primary B Cell Immune Activation
Mirabelli C; Jones MK; Young VL; Kolawole AO; Owusu I; Shan M; Abuaita B; Turula H; Trevino JG; Grigorova I; Lundy SK; Lyssiotis CA; Ward VK; Karst SM; Wobus CE
mBio; 2022 Apr; 13(2):e0017522. PubMed ID: 35404121
[TBL] [Abstract] [Full Text] [Related]
7. Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation.
Buday L; Vas V
Cancer Metastasis Rev; 2020 Dec; 39(4):1067-1073. PubMed ID: 32936431
[TBL] [Abstract] [Full Text] [Related]
8.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract] [Full Text] [Related]
9. Defining and Targeting Adaptations to Oncogenic KRAS
Santana-Codina N; Chandhoke AS; Yu Q; Małachowska B; Kuljanin M; Gikandi A; Stańczak M; Gableske S; Jedrychowski MP; Scott DA; Aguirre AJ; Fendler W; Gray NS; Mancias JD
Cell Rep; 2020 Mar; 30(13):4584-4599.e4. PubMed ID: 32234489
[TBL] [Abstract] [Full Text] [Related]
10. shp2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
[TBL] [Abstract] [Full Text] [Related]
11. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
[TBL] [Abstract] [Full Text] [Related]
12. An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy.
Pizzuto MS; Silic-Benussi M; Ciminale V; Elderfield RA; Capua I; Barclay WS
J Gen Virol; 2016 Sep; 97(9):2166-2179. PubMed ID: 27417501
[TBL] [Abstract] [Full Text] [Related]
13. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract] [Full Text] [Related]
14. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for treatment of pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract] [Full Text] [Related]
15. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
[TBL] [Abstract] [Full Text] [Related]
16. Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.
Réjiba S; Bigand C; Parmentier C; Masmoudi A; Hajri A
PLoS One; 2013; 8(8):e70594. PubMed ID: 23967078
[TBL] [Abstract] [Full Text] [Related]
17. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract] [Full Text] [Related]
18. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract] [Full Text] [Related]
19. The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma.
Yoon HJ; Hong JS; Shin WJ; Lee YJ; Hong KO; Lee JI; Hong SP; Hong SD
Oral Oncol; 2011 Nov; 47(11):1023-31. PubMed ID: 21824804
[TBL] [Abstract] [Full Text] [Related]
20. Palliative treatment of malignant gastroduodenal obstruction: Applications of self-expandable metal stent.
Nadır I; Parlak E; Küçükay F; Dışıbeyaz S; Cıçek B; Ozın Y; Ozdal Kuran S; Saşmaz N; Cumhur T; Sahın B
Turk J Gastroenterol; 2011 Feb; 22(1):6-9. PubMed ID: 21480104
[TBL] [Abstract] [Full Text] [Related]
[Next]
